Immunoadsorption in patients with neuromyelitis optica spectrum disorder.

Faissner, Simon; Nikolayczik, Johanna; Chan, Andrew; Gold, Ralf; Yoon, Min-Suk; Haghikia, Aiden (2016). Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Therapeutic advances in neurological disorders, 9(4), pp. 281-286. Sage 10.1177/1756285616646332

[img] Text
1756285616646332.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (473kB) | Request a copy

INTRODUCTION Neuromyelitis optica spectrum disorder (NMOSD) is a neuroinflammatory disorder of the central nervous system, distinct from multiple sclerosis by affecting predominantly the optic nerve and the spinal cord, and mediated by antibodies directed against aquaporin 4 (AQP4-ab) as a possible pathomechanistic hallmark of NMOSD. Therapeutic options include immunosuppression with steroids or B-cell-depleting agents as baseline therapies, as well as plasma exchange (PLEX) and/or immunoadsorption (IA) during relapses. Until now, data concerning the efficacy of IA alone are scarce. METHODS Visual evoked potentials (VEPs), visual acuity and changes of symptoms at relapse leading to admission in NMOSD patients (n = 10) treated with IA in a single-centre setting were evaluated retrospectively. RESULTS All patients profited from the procedure and showed an amelioration of admission symptoms. Three patients improved in visual acuity, another three patients remained stable, whereas five patients showed an improvement in VEPs. DISCUSSION In this small cohort, IA constitutes a valid therapeutic option for patients with NMOSD as an equivalent to PLEX. Analysis in larger cohorts is warranted.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DCR Unit Sahli Building > Forschungsgruppe Neurologie
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Chan, Andrew

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1756-2856

Publisher:

Sage

Language:

English

Submitter:

Stefanie Hetzenecker

Date Deposited:

03 May 2017 10:15

Last Modified:

03 May 2017 10:15

Publisher DOI:

10.1177/1756285616646332

PubMed ID:

27366234

Uncontrolled Keywords:

aquaporin 4 antibodies; immunosuppressive treatment; multiple sclerosis-related disease; plasmapheresis

BORIS DOI:

10.7892/boris.94726

URI:

https://boris.unibe.ch/id/eprint/94726

Actions (login required)

Edit item Edit item
Provide Feedback